Agenda: Administrative Reports and Program Development

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894

Closed: June 15, 2000, 9 am to 12 pm

Agenda: To review and evaluate grant applications

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894

Closed: June 15, 2000, 12 pm to 1:30 pm

Agenda: To review and evaluate resource grant applications

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894

Contact Person: Sharee Pepper, Phd, Scientific Review Administrator, Health Scientist Administrator, Office of Extramural Programs, National Library of Medicine, 6705 Rockledge Drive Suite 301, Bethesda, MD 20892, (301) 594–4933

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: May 10, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–12540 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: May 30, 2000.

Time: 10 am to 1 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Dharam S. Dhindsa, DVM, Phd, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5126, MSC 7854, Bethesda, MD 20892, (301) 435–1174, dhindsad@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: May 30–31, 2000.

Time: 6 pm to 5 pm.

Agenda: To review and evaluate grant applications.

Place: American Inn of Bethesda, 8130 Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Ramesh K. Nayak, Phd, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5146, MSC 7840, Bethesda, MD 20892, (301) 435–1026.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: May 31–June 1, 2000.

Time: 8:30 pm to 5 pm.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 5520 Wisconsin Ave, Palladian West, Chevy Chase, MD 20815.

Contact person: Gamil C. Debbas, PhD, Scientific Review Adminsitrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7844, Bethesda, MD 20892, (301) 435–1018.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: May 31, 2000.

Time: 1 pm to 4 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Dharam S. Dhindsa, DVM, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5126, MSC 7854, Bethesda, MD 20892, (301) 435–1174, dhindsad@csr.nih.gov

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: May 31, 2000.

Time: 2 pm to 4 pm.

*Agenda:*To review and evaluate grant applications and/or proposals

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Syed Amir, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6168, MSC 7892, Bethesda, MD 20892 (301) 435–1043.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 10, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–12537 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Uridine Prodrug Analogues: Uses in Cancer Diagnosis and Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in PCT Patent Application S/N PCT/US98/23109 (23109) entitled, ''Antitumor Uridine Analogs'' which was filed on October 10, 1998 and claims priority to U.S. Patent Application S/N 60/063,587 entitled, ''Diagnosis and Treatment of Tumors with Drugs Activated by Thymidylate Synthase,'' which was filed on October 10, 1997 to Nascent Pharmaceuticals LLC of San Francisco, California. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics and diagnostics for the detection and treatment of breast and gastrointestinal cancers.

DATES: Only *written* comments and/or license applications which are received by the National Institutes of Health on or before July 17, 2000 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Richard U. Rodriguez, M.B.A., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852–3804. Telephone: (301) 496–7056, X287; Facsimile (301) 402–0220; E-mail rr154z@nih.gov.

SUPPLEMENTARY INFORMATION: The technology claimed in '23109 relates to methods, compounds and compositions for diagnosing and/or treating cancers with anti-tumor agents activated by thymidylate synthase (TS) and/or thymidine kinase (TK). In addition, the invention relates to the preparation and use of positron emitting nucleoside analogues for imaging applications.

TS is an essential enzyme for DNA synthesis, and it has been shown to be

more abundantly expressed in tumor cells than in normal cells. Historically, scientists have tried to capitalize upon this overexpression and have attempted to inhibit TS activity with the goal of shrinking tumors and/or killing tumor cells. For example, fluorouracil and floxuridine have been used to treat breast, colon, pancreas, stomach, ovarian and head/neck carcinomas, but the effectiveness of these approaches have been limited because many tumors are inherently resistant to these treatments, and even those that are initially sensitive, develop resistance during the course of treatment. It was subsequently shown, that a strong correlation exists between resistance and high level expression of TS.

The inventors have proceeded along another route, again, attempting to capitalize upon the high levels of TS in tumor cells. Instead of trying to inhibit TS activity, they have proposed the introduction of uridine analogue prodrugs into cancer cells. These prodrugs would then be converted to more toxic thymidine analogues. This approach seems to avoid the observed problems of TS inhibition and shows great promise.

Detection and diagnostic applications for this technology are also possible. In particular, the success of this type of strategy would be contingent upon the extent of prodrug incorporation into DNA and therefore, the analysis of a tumor cell's DNA could provide diagnostic information regarding the optimal therapy for a specific tumor type. Traditionally, methods to determine growth rates have been invasive, but this technology would provide for non-invasive external imaging methods which would avoid the need for biopsies as well as providing for the capability of scanning larger areas of the body.

Thymidine is an excellent probe for monitoring growth/DNA synthesis, but it cannot be used in these situations because it is quickly degraded in the body. Analogues of thymidine would obviate this problem and could be produced upon conversion of the contemplated uridine analogue prodrugs.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 25, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 00–12548 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4570–N–02]

Office of the Assistant Secretary for Public and Indian Housing; Notice of Funding Availability for Fair Share Allocation of Incremental Voucher Funding Fiscal Year 2000; Amendments to NOFA and Reopening of Application Period

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice of Fund Availability (NOFA); Amendments and Reopening of Application Period.

SUMMARY: On March 10, 2000, HUD published its FY 2000 NOFA for Fair Share Allocation of Incremental Voucher Funding (''Fair Share NOFA''). This document amends the selection criteria of this NOFA primarily to better reflect the appropriate weight in points that should have been assigned to the ''housing needs'' selection criterion so that need is the most important basis for allocating incremental voucher funding. As discussed in more detail in the Supplementary Information section of this notice, the points of other selection criteria are also revised to better reflect their appropriate weight, and the separate criterion for portability is removed. This notice also explains that HUD will substitute the number of ''contracted units'' for ''HUD-approved budget'' the number of certificates and vouchers on the latest HUD-approved budget when the number of a PHA's contracted units is higher than the number of a PHA's budgeted units.

The application period for the Fair Share NOFA closed on April 24, 2000. This notice reopens the application period for an additional 30 day period.

DATES: Applications are due on June 19, 2000.

Applicants that already submitted applications by the April 24, 2000, application due date, need not resubmit a new application, and need not amend their applications. Applicants that already submitted applications, however, may submit new or amended applications if they so choose.

SUPPLEMENTARY INFORMATION:

Background—March 10, 2000 NOFA

If you are interested in applying for funding under the Fair Share NOFA, and did not apply earlier, please review the entire Fair Share NOFA, published on March 10, 2000 (65 FR 13222). Except for the reopening of the application period and the revisions made by this document, all other provisions of the Fair Share NOFA are unchanged and remain applicable.

The March 10, 2000 Fair Share NOFA will provide you with detailed information regarding the submission of an application, Section 8 program requirements, the application selection process to be used by HUD in selecting applications for funding, and other valuable information relative to a PHA's application submission and participation in the program covered by this NOFA. The March 10, 2000 Fair Share NOFA is also available on HUD's internet site at http://www.hud.gov under ''Funds Available.'' This **Federal Register** notice amending the March 10, 2000 Fair Share NOFA is also available at the same HUD web site.

Reopening of Application Period

Application Due Date. Your completed application (an original and two copies) or any amendment to an earlier submitted application (also an original and two copies) is due on or before June 19, 2000 at the addresses shown below.

As noted earlier, applicants that already submitted applications by the April 24, 2000, application due date, need not resubmit a new application, and need not amend their applications. Applicants that already submitted applications, however, may submit new or amended applications if they so choose.

Submission of new or amended applications should clearly identify the name of the applicant, the applicant HA code (*e.g.* CA002), and whether the information submitted is new and replaces a previously submitted application in its entirety or is an addendum to the previously submitted application.

Address for Submitting Applications. Submit your original application or your original application amendment and one copy to Michael E. Diggs, Director